News for CLBS Stock

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group Caladrius Biosciences to Present at the BIO International Convention 2022 Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Time Caladrius Biosciences Receives $2.3 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program Caladrius Biosciences to Present at the BIO CEO & Investor Conference Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022 Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results Caladrius Biosciences to Host Third Quarter 2021 Financial Results Conference Call on Thursday, November 4th at 4:30 p.m. Eastern Time Caladrius Biosciences Announces Participation in Upcoming Conferences in October 2021 Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Bryn Pharma Appoints Pharmaceutical Industry Veteran Anne Clem Whitaker to Its Board of Directors Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time Caladrius Biosciences to Present at Zooming with LD Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021 Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021 Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time Caladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules Caladrius Biosciences Closes $25.0 Million Private Placement Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021 Caladrius Biosciences Announces $25.0 Million Private Placement Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021 Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020 Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360° Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa Caladrius Biosciences to Present at the BIO Investor Forum Digital Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference Caladrius Biosciences to Present at the LD 500 Virtual Conference on September 1, 2020 at 11:40 AM Eastern Time Caladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results Caladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020 Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions Caladrius Biosciences Closes $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Caladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Caladrius Biosciences to Host First Quarter 2020 Financial Results Conference Call on Thursday, May 7, 2020